A randomized, phase II study of pazopanib in castrate-sensitive prostate cancer: a University of Chicago Phase II Consortium/Department of Defense Prostate Cancer Clinical Trials Consortium study

A phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer

(2010) Joel Picus et al.   CANCER

Phase II Trial of Bevacizumab, Thalidomide, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer

(2010) Yang-Min Ning et al.   JOURNAL OF CLINICAL ONCOLOGY

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

(2010) Cora N. Sternberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy

(2009) G. Sonpavde et al.   ANNALS OF ONCOLOGY

Phase II study of sunitinib in men with advanced prostate cancer

(2009) M. Dror Michaelson et al.   ANNALS OF ONCOLOGY

Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer

(2009) Jeanny B. Aragon-Ching et al.   BJU INTERNATIONAL

Potential Benefits of Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer: A Systematic Review of the Literature

(2009) Per-Anders Abrahamsson   EUROPEAN UROLOGY

A Double-Blind Randomized Crossover Study of Oral Thalidomide Versus Placebo for Androgen Dependent Prostate Cancer Treated With Intermittent Androgen Ablation

(2009) William D. Figg et al.   JOURNAL OF UROLOGY